Results with dacomitinib (PF-00299804), an irreversible PAN-HER tyrosine kinase inhibitor, in a phase II cohort of patients with HER2-mutant or amplified lung cancers Meeting Abstract
| Authors: | Kris, M. G.; Camidge, D. R.; Giaccone, G.; Hida, T.; O'Connell, J.; Taylor, I.; Zhang, H.; Gold-Berg, Z.; Jänne, P. A. |
| Abstract Title: | Results with dacomitinib (PF-00299804), an irreversible PAN-HER tyrosine kinase inhibitor, in a phase II cohort of patients with HER2-mutant or amplified lung cancers |
| Meeting Title: | 15th World Conference on Lung Cancer (IASLC) |
| Keywords: | lung cancer; tyrosine kinase inhibitor; phase ii; dacomitinib |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 8 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2013 Oct 27-31 |
| Meeting Location: | Sydney, Australia |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2013-11-01 |
| Start Page: | S609 |
| End Page: | S610 |
| Language: | English |
| ACCESSION: | WOS:000339624903014 |
| PROVIDER: | wos |
| DOI: | 10.1097/01.JTO.0000438438.14562.c8 |
| Notes: | Meeting Abstract: P1.11-032 -- Source: Wos |
